Real-world treatment patterns and cost per patient achieving treatment targets among tirzepatide and semaglutide initiators in US patients with type 2 diabetes. (PubMed, J Manag Care Spec Pharm) - Sep 30, 2026 - "Adults with T2D initiating tirzepatide (Mounjaro only) or semaglutide (Ozempic only) from May 2022 to May 2023 were propensity score matched and classified as naive or non-naive based on GLP-1 RA exposure in the 6 months before initiation. In this real-world analysis, tirzepatide demonstrated better adherence, persistence, and A1c and weight reductions and lower T2D-Rx cost per responder for the most stringent treatment targets than semaglutide in both GLP-1 RA-naive and non-naive patients with T2D. These findings support the clinical and economic value of tirzepatide for achieving meaningful treatment outcomes in real-world patient populations."
HEOR • Journal • Real-world evidence • Retrospective data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
|
|
Carlos Vallarino; Chia-Chen Teng; Emma L Richard; Juan M Maldonado; Kendra Terrell; Meredith M Hoog; Michael Grabner
|